Norgine Company Profile

18:05 EDT 23rd June 2018 | BioPortfolio

Founded in 1906, Norgine is a specialty pharmaceutical company with an extensive pan-European presence. Throughout our long history, we have sought to develop and market high quality, innovative products for the benefit of both patients and physicians. We are committed to developing products not only to treat life-threatening conditions but, importantly, to improve the quality of life for patients with a range of acute and chronic illnesses. We have a long standing tradition of building relationships, based on the highest standards, with patients, physicians, employees, partners and other key stakeholders.


Chaplin HouseWidewater Place
Moorhall Road
United Kingdom


Phone: 44 1895 453710
Fax: 44 1895 453711

News Articles [15 Associated News Articles listed on BioPortfolio]

PLENVU® (NER1006) de Norgine reçoit l'approbation de l'Autriche, de l'Australie, de la ...

Norgine B.V. a annoncé aujourd'hui que les autorités réglementaires autrichiennes, françaises, irlandaises, italiennes et portugaises ont accordé une autorisation de mise sur le marché au Re...

Norgine anuncia el estudio Prosper en Hepatology, Medicine and Policy Journal[i]

PROSPER es el primer estudio de evidencia del mundo real financiado por Norgine sobre la experiencia de pacienteseuropeos y australianoscon encefalopatía hepática tomando Read more...

PLENVU® (NER1006) von Norgine erhält australische, französische, irische, italienische, ...

Norgine B.V. gab heute bekannt, dass ihnen von den französischen, irischen, italienischen, österreichischen und portugiesischen Aufsichtsbehörden für ihr Produkt PLENVU®, das der Darmreinigung ...

Norgine's bowel cleansing drug gains marketing approval in 5 European countries

Norgine's bowel cleanser Plenvu gained marketing approval from regulatory authorities in Austria, Ireland, France, Italy and  -More- 

Norgine gibt Veröffentlichung des Studiendesigns PROSPER im Magazin Hepatology, Medicine and ...

Norgine B.V. gab heute die Veröffentlichung des Studiendesigns von PROSPER (The Prospective Real-world Outcomes Study of Hepatic Encephalopathy Patients' Experience on Rifaximin-α) in der Zeitschr...

Norgine annonce la publication du modèle d'étude PROSPER dans le Hepatology, Medicine and ...

Norgine B.V. a annoncé aujourd'hui la publication du modèle d'étude PROSPER (étude prospective sur les résultats de l'expérience des patients atteints d'encéphalopathie hépatique prenant de ...

Norgine B.V. Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 15022018] Prices from USD $350

Norgine B.V. Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Norgine B.V. Mergers Acquisitions MA, Partnerships Alliances and Investments report includes ...

Norgine to acquire Merus

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

Sensory Properties of Bowel Cleansing Solutions

Samples of 4 commercially available bowel cleansing solutions, namely PEG-electrolyte + ascorbic acid (PEG-Asc, Moviprep®, Norgine, UK), PEG-electrolyte (PEG, Fortrans® Ibsen, France), s...

Companies [0 Results]


More Information about "Norgine" on BioPortfolio

We have published hundreds of Norgine news stories on BioPortfolio along with dozens of Norgine Clinical Trials and PubMed Articles about Norgine for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Norgine Companies in our database. You can also find out about relevant Norgine Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record